Limiting Treatment Duration Improves Cost Effectiveness in CLL

While multiple treatment options for the first-line treatment of chronic lymphocytic leukemia (CLL) exist, they can be prohibitively expensive. That’s why researchers are currently looking into ways to limit the duration of treatment and potentially save money.

At the American Society of Hematology’s 2019 Annual Meeting, Dr. Matthew Davids of the Dana Farber Cancer Institute and Harvard Medical School spoke with CURE’s sister publication OncLive about his research into the potential cost effectiveness of a fixed duration of Venclexta (venetoclax) plus Gazyva (obinutuzumab) in this disease, and explained why limiting the duration of treatment could be beneficial for patients.

View more at



CURE: Combining science and humanity to make cancer understandable.

cancer,oncology,cancer care,cure magazine,health,